Investors haven’t been too enamored with Celgene (NASDAQ: CELG) and Bristol-Myers Squibb (NYSE: BMY) lately. Both have super-successful cancer drugs and are making plenty of money. However, neither stock has performed very well so far in 2017.
Which of these two drug stocks is the better pick for long-term investors? Here’s how Celgene and Bristol-Myers Squibb compare.
Image source: Getty Images.